Atypical mood stabilizers: A 'typical' role for atypical antipsychotics

Acta Psychiatrica Scandinavica, Supplement

Volumn 111, Issue 426, 2005, Pages 29-38

  Malhi, G S ^a,b,c   Berk, M ^d,e,f   Bourin, M ^g   Ivanovski, B ^a,b   Dodd, S ^d,e   Lagopoulos, J ^a,b   Mitchell, P B ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e BARWON HEALTH   (Australia)

^f ORYGEN RESEARCH CENTRE   (Australia)

^g UNIVERSITÉ DE NANTES   (France)

Author keywords

Atypical antipsychotics; Bipolar disorder; Mood stabilizers; Treatment

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOZAPINE; HALOPERIDOL; LITHIUM; LORAZEPAM; MOOD STABILIZER; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; SULPIRIDE; SULTOPRIDE; THIAZOLE DERIVATIVE;

AGRANULOCYTOSIS; BIPOLAR DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; LONG TERM CARE; MAINTENANCE THERAPY; MANIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; QT PROLONGATION; RELAPSE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; TORSADE DES POINTES; TREATMENT OUTCOME; WEIGHT GAIN; AFFECT; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

AFFECT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CLOZAPINE; DIBENZOTHIAZEPINES; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISPERIDONE; SULPIRIDE; THIAZOLES;

EID: 18044388000     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2005.00524.x     Document Type: Review

References (95)

1. MITCHELL P, MALHI G, BALL J. Major advances in bipolar disorder. Med J Aust 2004;181:207-210.
2. GOODWIN F, JAMISON K. Manic-depressive illness. New York, USA: Oxford University Press, 1990.
3. MALHI G, IVANOVSKI B, SZEKERES V, OLLEY A. Bipolar disorder: it's all in your mind? The neuropsychological profile of a biological disorder. Can J Psychiatry 2004;49:813-819.
4. AKISKAL H, PINTO O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am 1999;22:517-534.
5. BERK M, DODD S, MALHI G. Bipolar missed states: the diagnosis and clinical salience of bipolar mixed states. Aust N Z J Psychiatry 2005;39:215-221.
6. MITCHELL P, MALHI G. Bipolar depression - phenomenological overview and clinical characteristics. Bipolar Disord 2004;6:530-539.
7. MALHI G, MITCHELL P, SALIM S. Bipolar depression: management options. CNS Drugs 2003;17:9-25.
8. MITCHELL P, MALHI G. The expanding pharmacopoeia for bipolar disorder. Annu Rev Med 2002;53:173-188.
9. KETTER T, WANG P, NOWAKOWSKA C, MARSH W. New medication treatment options for bipolar disorder. Acta Psychiatr Scand 2004;110(suppl. 422):18-33.
10. YATHAM L. Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disord 2003;5(suppl. 2):7-19.
11. TOHEN M, SANGER T, MCELROY S et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH study group. Am J Psychiatry 1999;156:702-709.
12. TOHEN M, JACOBS T, GRUNDY S et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo- controlled study. The olanzapine HGGW study group. Arch Gen Psychiatry 2000;57:841-849.
13. BALDESSARINI RJ, HENNEN J, WILSON M et al. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J Clin Psychopharmacol 2003;23:370-376.
14. TOHEN M, GOLDBERG JF, GONZALEZ-PINTO ARRILLAGA AM et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-1226.
15. SHI L, NAMJOSHI MA, ZHANG F et al. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int Clin Psychopharmacol 2002;17:227-237.
16. BERK M, ICHIM L, BROOK S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999;14:339-343.
17. TOHEN M, BAKER R, ALTSHULER L et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-1017.
18. TOHEN M, CHENGAPPA K, SUPPES T et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-69.
19. KECK P Jr, MARCUS R, TOURKODIMITRIS S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-1658.
20. SACHS G, SANCHEZ R, MARCUS R et al. Aripiprazole versus placebo in acute mania: results from a second study. 55th Meeting of the Institute of Psychiatric Services. Boston, MA, USA, 2003.
21. HADJAKIS W, MARCUS R, ABOU-GHARBIA N et al. Aripiprazole in acute mania: results from a second placebo-controlled study. Bipolar Disord 2004;6(suppl. 1):39-40.
22. BOURIN M, AUBY P, SWANINK R et al. Aripiprazole versus haloperidol for maintained treatment effect in acute mania. Annual Meeting of the American Psychiatric Association, May 17-22, 2003. San Francisco, USA, 2003.
23. BRECHER M, HUIZAR K. Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1). Bipolar Disord 2003;5(suppl. 1):35-36.
24. BRECHER M, HUIZAR K. Quetiapine vs. placebo for acute mania associated with bipolar disorder (STAMP 1). Bipolar Disord 2003;5(suppl. 1):35.
25. JONES M, HUIZAR K. Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1 and STAMP 2). Bipolar Disord 2003;5(suppl. 1):57.
26. JONES M, HUIZAR K. Quetiapine as monotherapy for mania associated with bipolar disorder. 43rd Annual NCDEU Conference. Boca Raton, FL, USA, 2003:158.
27. MULLEN J, PAULSSON B. Quetiapine in combination with mood stabilizers for the treatment of acute mania associated with bipolar disorder. Bipolar Disord 2003;5(suppl. 1):70.
28. SACHS G, CHENGAPPA K, SUPPES T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213-223.
29. YATHAM LN, MULLEN J. Quetiapine in combination with mood stabiliser for the treatment of acute mania associated with bipolar disorder. Int J Neuropsychopharmacol 2004;7(suppl. 1):s330.
30. KECK PE Jr, VERSIANI M, POTKIN S, WEST SA, GILLER E, ICE K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-748.
31. WEISLER R, DUNN J, ENGLISH P. Adjunctive ziprasidone for bipolar mania: short and long-term data. Int J Neuropsychopharmacol 2004;7(suppl. 1):s327.
32. HIRSCHFELD R, KECK PE, KARCHER K, KRAMER M, GROSSMAN F. Rapid antimanic effect of risperidone monotherapy: a three-week, multicenter, randomized, double-blind, placebo-controlled trial. American Psychiatric Association Annual Meeting, May 17-22, 2003. San Francisco, CA, USA, 2003.
33. KHANNA S, VIETA E, LYONS B, GROSSMAN F, KRAMER M. Risperidone in the treatment of acute bipolar mania: a double-blind, placebo controlled study of 290 patients. Eur Neuropsychopharmacol 2003;13(suppl. 4):s314-315.
34. SEGAL J, BERK M, BROOK S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998;21:176-180.
35. VIETA E, BRUGUE E, GOIKOLEA JM et al. Acute and continuation risperidone monotherapy in mania. Hum Psychopharmacol 2004;19:41-45.
36. VIETA E, HERRAIZ M, PARRAMON G, GOIKOLEA J, FERNANDEZ A, BENABARRE A. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J Affect Disord 2002;72:15-19.
37. YATHAM L, BINDER C, RICCARDELLI R, LEBLANC J, CONNOLLY M, KUSUMAKAR V. Risperidone in acute and continuation treatment of mania. Int Clin Psychopharmacol 2003;18:227-235.
38. YATHAM L, GROSSMAN F, AUGUSTYNS I, VIETA E, RAVINDRAN A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International double-blind, randomised controlled trial. Br J Psychiatry 2003;182:141-147.
39. SACHS G, GROSSMAN F, GHAEMI S, OKAMOTO A, BOWDEN C. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146-1154.
40. BARBINI B, SCHERILLO P, BENEDETTI F, CRESPI G, COLOMBO C, SMERALDI E. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol 1997;12:109-112.
41. DEGNER D, BLEICH S, MULLER P, HAJAK G, ADLER L, RUTHER E. Clozapine in the treatment of mania. J Neuropsychiatry Clin Neurosci 2000;12:283.
42. MEEHAN K, ZHANG F, DAVID S et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001:21:389-397.
43. DANIEL DG, BROOK S, WARRINGTON L, LOEBEL A, MURRAY S. IM ziprasidone in agitated psychotic patients with bipolar diagnoses. Int J Neuropsychopharmacol 2004;7(suppl. 1): s327.
44. JUDD L, AKISKAL H, SCHETTLER P et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537.
45. TOHEN M, VIETA E, CALABRESE J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-1088.
46. SAJATOVIC M, MULLEN JA, SWEITZER DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002;63:1156-1163.
47. MILEV RV, ABRAHAM G, VOUTSILAKOS F, HOAKEN P. Open-label add-on quetiapine for bipolar depression: an eight-week trial. American Psychiatric Association Annual Meeting, May 1-6, 2004. New York, NY, USA, 2004.
48. CALABRESE J, MACFADDEN W, MCCOY R, MINKWITZ M, WILSON E, MULLEN J. Double-blind, placebo-controlled study of quetiapine in bipolar depression. American Psychiatric Association 2004 Annual Meeting-Abstracts on Disk. 157th Annual Meeting of American Psychiatric Association, American Psychiatric Association, New York, NY, USA, 2004.
49. PARKER G, MALHI G. Are atypical antipsychotic drugs also atypical antidepressants? Aust N Z J Psychiatry 2001;35:631-638.
50. VIETA E, GASTO C, COLOM F et al. Role of risperidone in bipolar II: an open 6-month study. J Affect Disord 2001;67(1-3):213-219.
51. MALHI G, CHECKLEY S. Olanzapine in the treatment of psychotic depression. Br J Psychiatry 1999;174:460.
52. TOHEN M, BOWDEN C, CALABRESE J et al. Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double-blind, placebo-controlled 12-month clinical trial. Bipolar Disord 2003;5(suppl. 1):89.
53. VIETA E, GOIKOLEA J, CORBELLA B et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 2001;62:818-825.
54. VIETA E, PARRAMON G, PADRELL E et al. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002;4:335-340.
55. SANGER T, TOHEN M, VIETA E et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord 2003;73(1-2):155-161.
56. GREEN A, TOHEN M, PATEL J et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000;157:982-986.
57. CIAPPARELLI A, DELL'OSSO L, PINI S, CHIAVACCI M, FENZI M, CASSANO G. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 2000;61:329-334.
58. SUPPES T, WEBB A, PAUL B, CARMODY T, KRAEMER H, RUSH A. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156:1164-1169.
59. VIETA E, GASTO C, COLOM F, MARTINEZ A, OTERO A, VALLEJO J. Treatment of refractory rapid cycling bipolar disorder with risperidone. J Clin Psychopharmacol 1998;18:172-174.
60. MCELROY S, FRYE M, DENICOFF K et al. Olanzapine in treatment-resistant bipolar disorder. J Affect Disord 1998;49:119-122.
61. NARENDRAN R, YOUNG C, VALENTI A, PRISTACH C, PATO M, GRACE J. Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. J Clin Psychiatry 2001;62:509-516.
62. GHAEMI S, KATZOW J. The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann Clin Psychiatry 1999;11:137-140.
63. FRYE M, KETTER T, LEVERICH G et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15.
64. TOHEN M, KETTER TA, ZARATE CA et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160:1263-1271.
65. TOHEN M, MARNEROS A, BOWDEN CL et al. Olanzapine vs. lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Bipolar Disord 2003;5(suppl. 1):89.
66. TOHEN M, BOWDEN CL, CALABRESE JR et al. Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double-blind, placebo-controlled 12-month clinical trial. Bipolar Disord 2003;5(suppl. 1):89.
67. TOHEN M, CHENGAPPA K, SUPPES T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs. mood stabiliser alone. Br J Psychiatry 2004;184:337-345.
68. MCQUADE RD, SANCHEZ R, MARCUS R et al. Aripiprazole for relapse prevention in bipolar disorder: a 26-week placebo controlled study. Int J Neuropsychopharmacol 2004;7(suppl. 1):s161.
69. GUILLE C, SACHS G, GHAEMI S. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000;61:638-642.
70. SACHS G, GUILLE C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999;60(suppl. 21):16-19.
71. NEMEROFF C. Safety of available agents used to treat bipolar disorder; focus on weight gain. J Clin Psychiatry 2003;64:532-539.
72. MALHI G. Weight gain: gained by waiting. Acta Psychiatr Scand 2003;108:249-251.
73. MCINTYRE R, MANCINI D, BASILE V, SRINIVASAN J, KENNEDY S. Antipsychotic-induced weight gain: bipolar disorder and leptin. J Clin Psychopharmacol 2003;23:323-327.
74. SANGER T, GRUNDY S, GIBSON P, NAMJOSHI M, GREANEY M, TOHEN M. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001;62:273-281.
75. OSSER D, NAJARIAN D, DUFRESNE R. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-770.
76. MEYER J. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002;63:425-433.
77. GIANFRANCESCO F, WHITE R, WANG R, NASRALLAH H. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003;23:328-335.
78. LINDENMAYER J, CZOBOR P, VOLAVKA J et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-296.
79. KORO C, FEDDER D, L'ITALIEN G et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-1026.
80. FULLER M, SHERMOCK K, SECIC M, GROGG A. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003;23:1037-1043.
81. GOODNICK P, JERRY J. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 2002;3:1773-1781.
82. DELBELLO M, SCHWIERS M, ROSENBERG H, STRAKOWSKI S. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002;41:1216-1223.
83. SAJATOVIC M, BRESCAN D, PEREZ D et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry 2001;62:728-732.
84. TANDON R. Safety and tolerability: how do newer generation 'atypical' antipsychotics compare? Psychiatr Q 2002;73:297-311.
85. MULLEN J, JIBSON M, SWEITZER D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23:1839-1854.
86. KECK P, MCELROY S. Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry 2003;64:1426-1435.
87. KECK P, MCELROY S, ARNOLD L. Ziprasidone: a new atypical antipsychotic. Expert Opin Pharmacother 2001;2:1033-1042.
88. KELLY D, LOVE R. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. Psychopharmacol Bull 2001;35:66-79.
89. ALLISON D, MENTORE J, HEO M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696.
90. ATKIN K, KENDALL F, GOULD D, FREEMAN H, LIBERMAN J, O'SULLIVAN D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996;169:483-488.
91. PACIA S, DEVINSKY O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994;44:2247-2249.
92. IQBAL M, RAHMAN A, HUSAIN Z, MAHMUD S, RYAN W, FELDMAN J. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003;15:33-48.
93. MONKUL S, MALHI G, SOARES J. Anatomical abnormalities in bipolar disorder: do they exist and do they progress? Aust N Z J Psychiatry 2005;39:222-226.
94. MALHI G, LAGOPOULOS J, OWEN A, YATHAM L. Bipolaroids: functional imaging in bipolar disorder. Acta Psychiatr Scand 2004;110(suppl. 422):46-54.
95. VIETA E, COLOM F. Psychological Interventions in Bipolar Disorder: from wishful thinking to an evidence-based approach. Acta Psychiatr Scand 2004;110(suppl. 422):34-38.